NAV

Foslevodopa

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Foslevodopa
DrugBank Accession Number
DB16683
Background

Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants With Advanced Parkinson's Disease).

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 277.169
Monoisotopic: 277.035138728
Chemical Formula
C9H12NO7P
Synonyms
  • 3-hydroxy-O-phosphono-L-tyrosine
  • Foslevodopa
  • Levodopa-4'-monophosphate
External IDs
  • ABBV-951
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Produodopa (AbbVie)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
VyalevFoslevodopa (240 mg / mL) + Foscarbidopa (12 mg / mL)SolutionSubcutaneousAbbvie2024-02-05Not applicableCanada flag

Categories

ATC Codes
N04BA07 — Foslevodopa and decarboxylase inhibitor
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
37NQZ0J76I
CAS number
97321-87-4
InChI Key
YNDMEEULGSTYJT-LURJTMIESA-N
InChI
InChI=1S/C9H12NO7P/c10-6(9(12)13)3-5-1-2-8(7(11)4-5)17-18(14,15)16/h1-2,4,6,11H,3,10H2,(H,12,13)(H2,14,15,16)/t6-/m0/s1
IUPAC Name
(2S)-2-amino-3-[3-hydroxy-4-(phosphonooxy)phenyl]propanoic acid
SMILES
N[C@@H](CC1=CC=C(OP(O)(O)=O)C(O)=C1)C(O)=O

References

General References
Not Available
ChemSpider
113330
ChEBI
192509
ChEMBL
CHEMBL4594379

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentParkinson's Disease (PD)2
3CompletedTreatmentParkinson's Disease (PD)2
1CompletedTreatmentParkinson's Disease (PD)3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionSubcutaneous
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.66 mg/mLALOGPS
logP-0.74ALOGPS
logP-1.3Chemaxon
logS-2.2ALOGPS
pKa (Strongest Acidic)1.26Chemaxon
pKa (Strongest Basic)9.41Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count5Chemaxon
Polar Surface Area150.31 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity59.95 m3·mol-1Chemaxon
Polarizability23.74 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00lr-0090000000-88917fd13fc22aa1cafa
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9020000000-b4611a6c2143f2082520
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00lr-0970000000-5bc3ba4e5cbcb8592b31
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9000000000-5e937135c9d10816e54b
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9000000000-455d394fad6c23f2fb80
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-053r-0900000000-524409450a9ad520ac0d
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at April 01, 2021 21:58 / Updated at April 24, 2024 19:06